To address these uncertainties, we conducted a systematic meta-analysis of the existing literature to evaluate the efficacy and safety of combining PD-1/PD-L1 and CTLA-4 inhibitors in CRC treatment. The gene discussed is PDCD1; the disease is colorectal carcinoma.